

# PCORnet® Population Insights Report

## *Characteristics of the Patient Population with Malignant Cancer Receiving Health Care Services Across PCORnet® Clinical Research Networks in 2025*

### Rationale for Network Query of PCORnet® Data Resources:

This report characterizes the population of patients with diagnosis codes for malignant cancer reflected in their medical record and encounters in a health care setting across PCORnet® between January 1, 2025 – December 31, 2025.

The report aligns with the Patient-Centered Outcomes Research Institute's® (PCORI®) strategic goal to demonstrate ways PCORnet can be used to address national-scale patient-centered comparative clinical effectiveness research (CER) questions. The results in this report may support planning for future patient-centered CER using PCORnet related to cancer care.

### Background on PCORnet®:

PCORnet is a large, distributed “network of networks” funded by PCORI to improve the nation’s capacity to efficiently conduct health research, particularly patient-centered CER.

The unique federated architecture of the network enables network sites to query clinical encounter data to identify patients and contact them for recruitment in research studies (with the appropriate regulatory and legal agreements). PCORnet has been used to conduct more than 300 studies, including pragmatic trials, observational research, and data science studies. [PCORnet® Population Insights Reports](#) are created to provide descriptive insights into the feasibility of research questions and the potential to recruit patients for future research using PCORnet.

At the time of this report, PCORnet® Network Partners include eight PCORnet® Clinical Research Networks (CRNs) with 78 partner sites in addition to Patient Partners and the Coordinating Center for PCORnet®. Collectively, these sites are connected to more than 50 million people in the United States and include large academic health systems, hospitals, federally qualified health centers, and community clinics.

For more information on the structure and governance of PCORnet, please see the [PCORnet® Playbook](#).

### Population Insights Report Description:

This report describes the results of a data query of the patients that had at least 1 face-to-face encounter and a recorded diagnosis code (e.g., ICD-10) at a health care setting across PCORnet between January 1 – December 31, 2025. The query used a 5-year “look-back” period between January 1, 2021 – December 31, 2025, to identify patients with diagnosis codes for specific malignant cancers that were reflected in the electronic health record. The query results will enhance public awareness of the population of patients with malignant cancer as well as utilization of health care services by these patients across sites participating in

PCORnet that potentially would be available for future health care research.

### Data Query Methodology and Criteria:

The Coordinating Center collaborated with PCORI to develop the specifications and criteria for this data query. Collaborators developed a comprehensive list of malignant cancers to be included in this query. The query identified demographic and geographic characteristics of the referenced patient population with at least 1 face-to-face encounter at a site participating in PCORnet during the 1-year query period (January 1 – December 31, 2025). From this patient population, the query characterized patients who had a diagnosis code for any of the given malignant cancers in their electronic health record within a 5-year period (January 1, 2021 – December 31, 2025). The data query also described additional co-occurring cancer conditions, cancer-related therapies and medications, procedures, and utilization of health care settings.

Additional methods and information used to specify the query and define the cohorts are available upon request by emailing [frontdoor@pcornet.org](mailto:frontdoor@pcornet.org).

The Coordinating Center programmed and distributed this data query to 74 partners in PCORnet.

### Population Insights Report Results:

Seventy-four (74) PCORnet partners contributed data to this report, reflecting the experience of patients with a diagnosis of malignant cancer reflected in their medical record between January 1, 2021 – December 31, 2025, who received health care services across sites participating in PCORnet in the 2025 calendar year.

Results of the query are provided in tables referenced below:

- **Table 1.** Demographic characteristics of the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, that received health care services across sites participating in PCORnet between January 1, 2025 – December 31, 2025. The table includes the patient population stratified by sites affiliated with National Cancer Institute designated Comprehensive Cancer Centers and community cancer care sites.
- **Table 2.** Care setting and geographic characteristics of the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, receiving health care services across sites participating in PCORnet between January 1, 2025 – December 31, 2025.
- **Table 3.** Demographic characteristics by cancer condition for the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, that received health care services across sites participating in PCORnet between January 1 – December 31, 2025.
- **Table 4.** Continued: Demographic characteristics by cancer condition for the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, that received health care services across sites participating in PCORnet between January 1, 2025 – December 31, 2025.
- **Table 5.** Co-occurring cancer conditions, cancer-related therapies and medications, and procedures for patients with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2025 – December 31, 2025, and a recorded diagnosis code for a malignant cancer condition between January 1, 2021 – December 31, 2025.
- **Table 6.** Continued: Co-occurring cancer conditions, cancer-related therapies and medications, and procedures for patients with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2025 – December 31, 2025, and a recorded diagnosis code for a malignant cancer condition between January 1, 2021 – December 31, 2025.

- **Table 7.** Characteristics of patients with malignant cancer conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1 – December 31, 2025, for selected cancer-related therapies and medications provided between January 1, 2025 – December 31, 2025.
- **Table 8.** Continued: Characteristics of patients with malignant cancer conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1 – December 31, 2025, for selected cancer-related procedures provided between January 1, 2025 – December 31, 2025.
- **Table 9.** Continued: Characteristics of patients with malignant cancer conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1 – December 31, 2025, for selected cancer-related procedures provided between January 1, 2025 – December 31, 2025.

### Limitations:

Data presented are descriptive and derived from diagnosis and procedure codes collected in the electronic health record (EHR) during health care encounters. Rows and percentages may not add up to a total due to missing values and/or if counts are less than 11. If counts are between 1-10, then they are reported as “-” to protect patient privacy and risk of identification from aggregate values as outlined in the [Data Privacy Statement for PCORnet®](#).

No inferential analyses were conducted to compare populations or test hypotheses, as these are descriptive data only. Limitations with any EHR data analysis are applicable to this data, including the possibility for misclassification due to imperfect algorithms and lack of consistent definition of enrollment to define cohorts, in addition to limitations associated with processes to collect clinical data during health care encounters, including collection of demographic information. Data should be interpreted with these limitations in mind.

To ensure PCORnet data resources are of high quality for research and to mitigate the limitations above, all PCORnet-accessible data resources undergo [rigorous quality curation](#) and screening as part of quarterly coordinated data quality assessment. For more information on data curation activities and strategies to improve data quality for PCORnet, please contact [frontdoor@pcornet.org](mailto:frontdoor@pcornet.org).

### Disclaimer:

PCORnet® is intended to improve the nation’s capacity to efficiently conduct patient-centered health research, particularly CER, by providing a large, highly representative network of health data, research expertise, and patient insights. PCORnet has been developed with funding from the Patient-Centered Outcomes Research Institute® (PCORI®).

Network queries that return only aggregate or limited data sets are covered by [the PCORnet® Master Data Sharing Agreement](#) (version 5.0), and site-level blanket Institutional Review Board approvals. The statements presented in this report do not necessarily represent the views of PCORI or other organizations participating in, collaborating with, or funding PCORnet.

For questions, comments, or suggestions related to this PCORnet® Front Door query or other PCORnet queries, please contact [frontdoor@pcornet.org](mailto:frontdoor@pcornet.org).

## Tables

**Table 1.** Demographic characteristics of the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, that received health care services across sites participating in PCORnet® between January 1, 2025 – December 31, 2025.<sup>1,2</sup> The table includes the patient population stratified by sites affiliated with National Cancer Institute-designated Comprehensive Cancer Centers and community cancer care sites.

	Total		Any Malignant Cancer		Comprehensive Cancer Center Affiliation <sup>4</sup>		Community Cancer Care <sup>4</sup>	
	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,361	100	4,001,326	7.5	2,340,015	58.5	1,661,311	41.5
<b>MEAN AGE (SD)</b>	41.6 (± 23.0)		65.5 (± 15.6)		66.0 (± 14.8)		64.7 (± 16.7)	
<b>AGE</b>								
Children 0-9	7,114,159	13.3	40,181	1.0	13,637	0.6	26,544	1.6
Children 10-19	6,546,740	12.2	51,175	1.3	22,967	1.0	28,208	1.7
Adults 20-34	8,506,737	15.9	119,774	3.0	62,740	2.7	57,034	3.4
Adults 35-54	12,332,629	23.0	593,008	14.8	338,748	14.5	254,260	15.3
Adults 55-64	6,711,380	12.5	747,973	18.7	452,043	19.3	295,930	17.8
Adults 65-74	6,819,169	12.7	1,197,997	29.9	723,542	30.9	474,455	28.6
Adults 75+	5,627,547	10.5	1,251,218	31.3	726,338	31.0	524,880	31.6
<b>SEX</b>								0.0
Female	30,102,354	56.1	2,086,140	52.1	1,191,809	50.9	894,331	53.8
Male	23,527,877	43.8	1,914,533	47.8	1,147,792	49.1	766,741	46.2
Unknown	20,442	<0.1	429	0.0	299	0.0	130	0.0
Missing <sup>3</sup>	7,688	<0.1	224	0.0	115	0.0	109	0.0
<b>RACE</b>								0.0
White	32,463,098	60.5	2,914,423	72.8	1,720,648	73.5	1,193,775	71.9
Black or African American	7,718,653	14.4	382,411	9.6	221,460	9.5	160,951	9.7
Asian	2,646,745	4.9	170,448	4.3	69,742	3.0	100,706	6.1
Multiple races	1,117,929	2.1	69,202	1.7	18,266	0.8	50,936	3.1
American Indian or Alaska Native	329,306	0.6	16,278	0.4	9,314	0.4	6,964	0.4
Native Hawaiian or Other Pacific Islander	126,378	0.2	6,718	0.2	3,368	0.1	3,350	0.2
Unknown	6,883,182	12.8	322,720	8.1	237,167	10.1	85,553	5.1
Missing <sup>3</sup>	2,373,070	4.4	119,126	3.0	60,050	2.6	59,076	3.6
<b>HISPANIC</b>				0.0				0.0
No	35,878,475	66.9	3,129,858	78.2	1,817,620	77.7	1,312,238	79.0
Yes	8,306,913	15.5	326,515	8.2	153,912	6.6	172,603	10.4
Unknown	4,760,041	8.9	280,485	7.0	164,351	7.0	116,134	7.0
Missing <sup>3</sup>	4,712,932	8.8	264,468	6.6	204,132	8.7	60,336	3.6
<b>PAYER STATUS LAST VISIT IN 2025</b>								
Private	21,961,944	40.9	1,233,102	30.8	631,560	27.0	601,542	36.2
Public	16,643,793	31.0	1,778,651	44.5	932,926	39.9	845,725	50.9
Other	1,916,823	3.6	98,743	2.5	66,760	2.9	31,983	1.9
Missing <sup>3</sup>	13,135,750	24.5	890,830	22.3	708,769	30.3	182,061	11.0

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Missing includes those values that are null, refuse to answer, and no information.

<sup>4</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 2.** Care setting and geographic characteristics of the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, receiving health care services across sites participating in PCORnet® between January 1 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Comprehensive Cancer Center Affiliation <sup>6</sup>		Community Cancer Care <sup>6</sup>	
	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,361	100	4,001,326	7.5	2,340,015	58.5	1,661,311	41.5
<b>CARE SETTING ENCOUNTER 2025</b>								
Ambulatory Visit	46,541,824	86.7	3,780,441	94.5	2,212,984	94.6	1,567,457	94.4
Emergency Department Visit	10,064,212	18.8	584,893	14.6	311,124	13.3	273,769	16.5
Telehealth	8,168,205	15.2	1,050,828	26.3	690,294	29.5	360,534	21.7
Inpatient Hospital Stay	3,357,126	6.3	490,729	12.3	272,641	11.7	218,088	13.1
Emergency to Inpatient Stay	1,381,185	2.6	269,588	6.7	145,136	6.2	124,452	7.5
Non-Acute Institutional Stay	671,746	1.3	81,983	2.0	69,036	3.0	12,947	0.8
Observation Stay	654,587	1.2	82,423	2.1	51,413	2.2	31,010	1.9
<b>U.S. CENSUS REGION</b>								
South	19,343,323	36.0	1,326,820	33.2	843,125	36.0	483,695	29.1
West	11,441,485	21.3	974,959	24.4	421,609	18.0	553,350	33.3
Northeast	9,615,009	17.9	669,498	16.7	349,102	14.9	320,396	19.3
Midwest	9,159,916	17.1	778,376	19.5	511,816	21.9	266,560	16.0
Other	790,267	1.5	61,514	1.5	60,491	2.6	1,023	0.1
Missing	3,308,310	6.2	190,159	4.8	153,872	6.6	36,287	2.2
<b>TOTAL UNIQUE PATIENT RECORDS WITH ADDRESS DATA IN U.S.</b>	49,859,672	92.9	3,735,373	93.4	2,095,802	89.6	1,639,571	98.7
<b>AREA DEPRIVATION INDEX (ADI) QUARTILE BASED ON 5-DIGIT ZIP<sup>3</sup></b>								
ADI Quartile 1 (Higher Socioeconomic Status)	20,632,953	38.5	1,715,917	42.9	900,228	38.5	815,689	49.1
ADI Quartile 2	9,548,787	17.8	732,910	18.3	422,386	18.1	310,524	18.7
ADI Quartile 3	10,580,710	19.7	755,844	18.9	470,614	20.1	285,230	17.2
ADI Quartile 4 (Lower Socioeconomic Status)	8,554,019	15.9	492,816	12.3	282,660	12.1	210,156	12.7
Missing <sup>4</sup>	4,341,892	8.1	303,839	7.6	264,127	11.3	39,712	2.4
<b>RURAL-URBAN COMMUTING AREA (RUCA) CODES BASED ON 5-DIGIT ZIP<sup>5</sup></b>								
Metropolitan Area	43,356,651	80.8	3,137,920	78.4	1,720,754	73.5	1,417,166	85.3
Micropolitan Area	3,792,576	7.1	335,852	8.4	216,985	9.3	118,867	7.2
Small Town	1,549,123	2.9	152,778	3.8	94,812	4.1	57,966	3.5
Rural	1,033,861	1.9	107,197	2.7	62,417	2.7	44,780	2.7
Missing <sup>4</sup>	3,926,150	7.3	267,579	6.7	245,047	10.5	22,532	1.4

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Area Deprivation Index (ADI): Patient 5-digit zip codes are mapped to socioeconomic status by normalized Area Deprivation Index (ADI) value (0-100). Lower values are associated with higher socioeconomic status (SES) and higher values are associated with lower SES. A ranking of 1 indicates the highest level of SES within the nation and an ADI with a ranking of 100 indicates the lowest level of SES. In this table, values are grouped into quartiles using the count of zip codes. Quartile 1 (Higher SES) represents the lowest range of ADI values and Quartile 4 (Lower SES) represents the highest range of ADI values (Q1=0-38, Q2=39-43, Q3=44-49, and Q4=50-100). For additional information regarding the ADI index, see the Neighborhood Atlas: <https://www.neighborhoodatlas.medicine.wisc.edu>. Note that the Area Deprivation Index (ADI) is designed for validity at the 9-digit zip or census block group level rather than the 5-digit zip level.

<sup>4</sup>Missing includes those values that are null, refuse to answer, and no information.

<sup>5</sup>Represented as combined [Rural-Urban Commuting Area \(RUCA\) codes](#) as referenced on [https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl\\_ruca4](https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl_ruca4). RUCA contains 10 primary and 21 secondary codes which delineate components of rural and urban areas and define county-level metropolitan (urban) and nonmetropolitan areas (i.e., micropolitan/large rural areas, small towns, and isolated rural areas).

<sup>6</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 3.** Demographic characteristics by cancer condition for the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, that received health care services across sites participating in PCORnet® between January 1 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Skin Cancer <sup>4</sup>		Breast Cancer <sup>4</sup>		Prostate Cancer <sup>4</sup>		Lung Cancer		Other Lymphomas <sup>4</sup>		Colon and Rectal Cancer <sup>4</sup>		Leukemia		Head, Neck, and Throat Cancer <sup>4</sup>		Thyroid Cancer <sup>4</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	817,552	20.4	723,400	18.1	640,257	16.0	239,246	6.0	225,545	5.6	223,757	5.6	200,284	5.0	178,445	4.5	171,902	4.3
<b>MEAN AGE (SD)</b>	41.6 (± 23.0)		65.5 (± 15.6)		70.0 (± 13.6)		64.8 (± 18.1)		71.4 (± 11.2)		69.8 (± 12.7)		65.1 (± 16.8)		65.8 (± 14.7)		61.5 (± 19.5)		66.5 (± 13.5)		56.6 (± 16.5)	
<b>AGE</b>																						
Children 0-9	7,114,145	13.3	40,181	1.0	1,892	0.2	4,411	0.6	2,999	0.5	1,354	0.6	2,053	0.9	1,203	0.5	8,002	4.0	946	0.5	791	0.5
Children 10-19	6,546,729	12.2	51,175	1.3	2,075	0.3	3,736	0.5	2,346	0.4	1,230	0.5	4,068	1.8	950	0.4	9,342	4.7	1,222	0.7	2,025	1.2
Adults 20-34	8,506,729	15.9	119,774	3.0	9,609	1.2	12,376	1.7	4,291	0.7	2,914	1.2	10,313	4.6	3,835	1.7	10,644	5.3	3,263	1.8	15,526	9.0
Adults 35-54	12,332,616	23.0	593,008	14.8	86,673	10.6	145,282	20.1	24,946	3.9	17,523	7.3	32,040	14.2	41,557	18.6	25,730	12.8	21,709	12.2	55,556	32.3
Adults 55-64	6,711,372	12.5	747,973	18.7	136,485	16.7	154,274	21.3	97,244	15.2	39,490	16.5	38,548	17.1	47,866	21.4	30,277	15.1	39,432	22.1	35,874	20.9
Adults 65-74	6,819,166	12.7	1,197,997	29.9	246,069	30.1	203,102	28.1	243,455	38.0	84,189	35.2	63,307	28.1	61,145	27.3	52,774	26.3	60,621	34.0	36,246	21.1
Adults 75+	5,627,553	10.5	1,251,218	31.3	334,749	40.9	200,219	27.7	264,976	41.4	92,546	38.7	75,216	33.3	67,201	30.0	63,515	31.7	51,252	28.7	25,884	15.1
<b>SEX</b>																						
Female	30,102,327	56.1	2,086,140	52.1	379,514	46.4	691,129	95.5	28,615	4.5	132,902	55.6	108,374	48.0	111,328	49.8	91,512	45.7	57,525	32.2	127,282	74.0
Male	23,527,859	43.8	1,914,533	47.8	437,926	53.6	32,166	4.4	611,531	95.5	106,321	44.4	117,146	51.9	112,405	50.2	108,745	54.3	120,891	67.7	44,590	25.9
Unknown	20,437	<0.1	429	<0.1	63	<0.1	65	<0.1	76	<0.1	12	<0.1	16	<0.1	12	<0.1	-	<0.1	18	<0.1	15	<0.1
Missing <sup>3</sup>	7,687	<0.1	224	<0.1	49	<0.1	40	<0.1	35	<0.1	0	0.0	0	0.0	12	<0.1	-	<0.1	11	<0.1	15	<0.1
<b>RACE</b>																						
White	32,463,446	60.5	2,914,423	72.8	716,776	87.7	503,628	69.6	449,126	70.1	171,034	71.5	164,449	72.9	155,106	69.3	148,149	74.0	134,120	75.2	119,567	69.6
Black or African American	7,718,854	14.4	382,411	9.6	8,378	1.0	82,079	11.3	92,464	14.4	27,375	11.4	19,870	8.8	26,215	11.7	16,829	8.4	14,155	7.9	11,944	6.9
Asian	2,646,846	4.9	170,448	4.3	8,401	1.0	43,131	6.0	21,481	3.4	14,002	5.9	10,362	4.6	11,908	5.3	7,762	3.9	7,828	4.4	11,935	6.9
Multiple races	1,118,057	2.1	69,202	1.7	7,384	0.9	16,202	2.2	11,150	1.7	4,185	1.7	4,375	1.9	4,407	2.0	3,810	1.9	2,522	1.4	3,483	2.0
American Indian or Alaska Native	329,332	0.6	16,278	0.4	1,396	0.2	3,114	0.4	2,276	0.4	1,116	0.5	914	0.4	1,205	0.5	842	0.4	809	0.5	817	0.5
Native Hawaiian or Other Pacific Islander	126,374	0.2	6,718	0.2	418	0.1	1,483	0.2	893	0.1	411	0.2	398	0.2	446	0.2	398	0.2	353	0.2	377	0.2
Unknown	6,882,412	12.8	322,720	8.1	60,302	7.4	51,795	7.2	43,020	6.7	14,958	6.3	18,070	8.0	17,661	7.9	16,920	8.4	13,992	7.8	16,193	9.4
Missing <sup>3</sup>	2,372,989	4.4	119,126	3.0	14,497	1.8	21,968	3.0	19,847	3.1	6,165	2.6	7,107	3.2	6,809	3.0	5,574	2.8	4,666	2.6	7,586	4.4
<b>HISPANIC</b>																						
No	35,878,756	66.9	3,129,858	78.2	681,234	83.3	570,362	78.8	512,096	80.0	193,183	80.7	176,146	78.1	171,269	76.5	156,644	78.2	140,831	78.9	127,622	74.2
Yes	8,307,242	15.5	326,515	8.2	25,170	3.1	64,249	8.9	44,482	6.9	15,142	6.3	21,301	9.4	22,492	10.1	19,168	9.6	12,725	7.1	21,913	12.7
Unknown	4,759,415	8.9	280,485	7.0	68,482	8.4	42,530	5.9	39,912	6.2	15,693	6.6	13,787	6.1	15,454	6.9	12,143	6.1	12,819	7.2	10,145	5.9
Missing <sup>3</sup>	4,712,897	8.8	264,468	6.6	42,666	5.2	46,259	6.4	43,767	6.8	15,228	6.4	14,311	6.3	14,542	6.5	12,329	6.2	12,070	6.8	12,222	7.1
<b>PAYER STATUS LAST VISIT IN 2025</b>																						
Private	21,961,944	40.9	1,233,102	30.8	242,216	29.6	257,633	35.6	155,588	24.3	51,864	21.7	66,019	29.3	68,346	30.5	58,281	29.1	47,752	26.8	75,225	43.8
Public	16,643,793	31.0	1,778,651	44.5	381,312	46.6	305,331	42.2	328,302	51.3	129,604	54.2	102,723	45.5	98,961	44.2	93,638	46.8	80,699	45.2	53,423	31.1
Other	1,916,823	3.6	98,743	2.5	17,539	2.1	15,685	2.2	15,883	2.5	6,769	2.8	5,128	2.3	5,607	2.5	5,023	2.5	4,987	2.8	4,499	2.6
Missing <sup>3</sup>	13,135,750	24.5	890,830	22.3	176,485	21.6	144,751	20.0	140,484	21.9	51,009	21.3	51,675	22.9	50,843	22.7	43,342	21.6	45,007	25.2	38,755	22.5

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Missing includes those values that are null, refuse to answer, and no information.

<sup>4</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 4.** Continued: Demographic characteristics by cancer condition for the patient population with a diagnosis code for any malignant cancer between January 1, 2021 – December 31, 2025, that received health care services across sites participating in PCORnet® between January 1 – December 31, 2025. <sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Kidney Cancer <sup>4</sup>		Bladder Cancer <sup>4</sup>		Endouterine Cancer <sup>4</sup>		Multiple Myeloma and Plasmacytoma <sup>4</sup>		Liver Cancer <sup>4</sup>		Brain Cancer <sup>4</sup>		Pancreatic Cancer <sup>4</sup>		Bone Cancer		Hodgkin Lymphoma <sup>4</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	159,505	4.0	148,394	3.7	118,827	3.0	113,601	2.8	81,677	2.0	75,952	1.9	69,364	1.7	37,782	0.9	34,758	0.9
<b>MEAN AGE (SD)</b>	41.6 (± 23.0)		65.5 (± 15.6)		65.9 (± 14.9)		72.5 (± 12.8)		65.8 (± 13.4)		67.5 (± 13.8)		65.2 (± 14.7)		46.2 (± 20.0)		67.1 (± 14.1)		54.9 (± 20.4)		49.9 (± 19.1)	
<b>AGE</b>																						
Children 0-9	7,114,145	13.3	40,181	1.0	2,127	1.3	715	0.5	491	0.4	896	0.8	1,267	1.6	4,556	6.0	476	0.7	934	2.5	265	0.8
Children 10-19	6,546,729	12.2	51,175	1.3	1,927	1.2	632	0.4	423	0.4	711	0.6	1,036	1.3	8,618	11.3	558	0.8	3,177	8.4	1,935	5.6
Adults 20-34	8,506,729	15.9	119,774	3.0	2,838	1.8	1,482	1.0	2,056	1.7	1,848	1.6	1,915	2.3	11,172	14.7	1,451	2.1	4,328	11.5	7,132	20.5
Adults 35-54	12,332,616	23.0	593,008	14.8	21,874	13.7	8,596	5.8	17,746	14.9	13,118	11.5	9,789	12.0	20,023	26.4	8,098	11.7	6,848	18.1	10,070	29.0
Adults 55-64	6,711,372	12.5	747,973	18.7	31,893	20.0	18,340	12.4	26,693	22.5	21,955	19.3	16,124	19.7	11,893	15.7	13,127	18.9	6,162	16.3	5,472	15.7
Adults 65-74	6,819,166	12.7	1,197,997	29.9	49,363	30.9	44,623	30.1	39,729	33.4	37,132	32.7	30,156	36.9	11,935	15.7	22,861	33.0	8,411	22.3	5,524	15.9
Adults 75+	5,627,553	10.5	1,251,218	31.3	49,483	31.0	74,006	49.9	31,689	26.7	37,941	33.4	21,390	26.2	7,755	10.2	22,793	32.9	7,922	21.0	4,360	12.5
<b>SEX</b>																						
Female	30,102,327	56.1	2,086,140	52.1	61,740	38.7	41,372	27.9	115,698	97.4	54,609	48.1	32,199	39.4	37,626	49.5	35,061	50.5	17,865	47.3	17,264	49.7
Male	23,527,859	43.8	1,914,533	47.8	97,752	61.3	106,995	72.1	3,117	2.6	58,971	51.9	49,461	60.6	38,309	50.4	34,295	49.5	19,914	52.7	17,480	50.3
Unknown	20,437	<0.1	429	<0.1	-	<0.1	16	<0.1	-	<0.1	15	<0.1	14	<0.1	14	<0.1	-	<0.1	-	<0.1	-	<0.1
Missing <sup>3</sup>	7,687	<0.1	224	<0.1	-	<0.1	11	<0.1	-	<0.1	0	0.0	0	0.0	0	0.0	-	<0.1	-	<0.1	-	<0.1
<b>RACE</b>																						
White	32,463,446	60.5	2,914,423	72.8	115,347	72.3	118,204	79.7	82,299	69.3	71,110	62.6	52,612	64.4	54,933	72.3	48,240	69.5	26,952	71.3	24,249	69.8
Black or African American	7,718,854	14.4	382,411	9.6	18,665	11.7	9,782	6.6	14,002	11.8	19,946	17.6	8,661	10.6	6,096	8.0	7,644	11.0	3,486	9.2	4,068	11.7
Asian	2,646,846	4.9	170,448	4.3	5,390	3.4	5,275	3.6	6,096	5.1	4,869	4.3	6,457	7.9	3,267	4.3	3,751	5.4	1,501	4.0	1,283	3.7
Multiple races	1,118,057	2.1	69,202	1.7	2,327	1.5	2,316	1.6	2,192	1.8	2,520	2.2	1,750	2.1	1,447	1.9	1,558	2.2	518	1.4	664	1.9
American Indian or Alaska Native	329,332	0.6	16,278	0.4	940	0.6	480	0.3	596	0.5	475	0.4	647	0.8	333	0.4	297	0.4	212	0.6	137	0.4
Native Hawaiian or Other Pacific Islander	126,374	0.2	6,718	0.2	255	0.2	150	0.1	399	0.3	224	0.2	248	0.3	151	0.2	132	0.2	97	0.3	52	0.1
Unknown	6,882,412	12.8	322,720	8.1	12,197	7.6	8,394	5.7	9,653	8.1	10,865	9.6	7,964	9.8	7,391	9.7	5,431	7.8	3,977	10.5	3,163	9.1
Missing <sup>3</sup>	2,372,989	4.4	119,126	3.0	4,384	2.7	3,793	2.6	3,590	3.0	3,592	3.2	3,338	4.1	2,334	3.1	2,311	3.3	1,039	2.7	1,142	3.3
<b>HISPANIC</b>																						
No	35,878,756	66.9	3,129,858	78.2	123,519	77.4	121,881	82.1	90,338	76.0	87,294	76.8	60,162	73.7	57,555	75.8	53,128	76.6	28,487	75.4	26,167	75.3
Yes	8,307,242	15.5	326,515	8.2	16,448	10.3	8,549	5.8	12,940	10.9	10,399	9.2	11,224	13.7	8,071	10.6	6,504	9.4	4,307	11.4	4,048	11.6
Unknown	4,759,415	8.9	280,485	7.0	9,771	6.1	8,803	5.9	7,597	6.4	7,073	6.2	5,351	6.6	5,633	7.4	4,803	6.9	2,590	6.9	2,112	6.1
Missing <sup>3</sup>	4,712,897	8.8	264,468	6.6	9,767	6.1	9,161	6.2	7,952	6.7	8,835	7.8	4,940	6.0	4,693	6.2	4,929	7.1	2,398	6.3	2,431	7.0
<b>PAYER STATUS LAST VISIT IN 2025</b>																						
Private	21,961,944	40.9	1,233,102	30.8	43,897	27.5	32,053	21.6	36,460	30.7	30,784	27.1	20,599	25.2	29,241	38.5	18,750	27.0	12,106	32.0	14,834	42.7
Public	16,643,793	31.0	1,778,651	44.5	74,921	47.0	82,090	55.3	54,104	45.5	54,858	48.3	39,391	48.2	26,262	34.6	32,313	46.6	15,101	40.0	10,800	31.1
Other	1,916,823	3.6	98,743	2.5	4,041	2.5	3,294	2.2	2,307	1.9	2,572	2.3	2,261	2.8	2,817	3.7	1,659	2.4	1,117	3.0	1,129	3.2
Missing <sup>3</sup>	13,135,750	24.5	890,830	22.3	36,646	23.0	30,957	20.9	25,956	21.8	25,387	22.3	19,426	23.8	17,632	23.2	16,642	24.0	9,458	25.0	7,995	23.0

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Missing includes those values that are null, refuse to answer, and no information.

<sup>4</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 5.** Co-occurring cancer conditions, cancer-related therapies and medications, and procedures for patients with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2025 – December 31, 2025, and a recorded diagnosis code for a malignant cancer condition between January 1, 2021 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Skin Cancer <sup>3</sup>		Breast Cancer <sup>3</sup>		Prostate Cancer <sup>3</sup>		Lung Cancer <sup>3</sup>		Other Lymphomas <sup>3</sup>		Colon and Rectal Cancer <sup>3</sup>		Leukemia <sup>3</sup>		Head, Neck, and Throat Cancer <sup>3</sup>		Thyroid Cancer <sup>3</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	817,552	20.4	723,400	18.1	640,257	16.0	239,246	6.0	225,545	5.6	223,757	5.6	200,284	5.0	178,445	4.5	171,902	4.3
<b>CANCER CONDITIONS (2021-2025)</b>																						
Skin cancer	817,552	1.5	817,552	20.4	817,552	100	33,165	4.6	43,031	6.7	16,824	7.0	17,453	7.7	12,513	5.6	15,038	7.5	28,055	15.7	6,964	4.1
Breast cancer	723,400	1.3	723,400	18.1	33,165	4.1	723,400	100	7,380	1.2	15,044	6.3	9,212	4.1	9,782	4.4	7,356	3.7	4,526	2.5	8,356	4.9
Prostate cancer	640,257	1.2	640,257	16.0	43,031	5.3	7,380	1.0	640,257	100	10,908	4.6	10,628	4.7	10,222	4.6	8,984	4.5	8,144	4.6	4,029	2.3
Other cancers	627,355	1.2	627,355	15.7	66,034	8.1	43,512	6.0	29,913	4.7	45,804	19.1	17,006	7.5	36,803	16.4	14,076	7.0	57,619	32.3	11,301	6.6
Metastatic cancer	622,313	1.2	622,313	15.6	72,501	8.9	124,657	17.2	92,078	14.4	90,037	37.6	18,285	8.1	69,230	30.9	15,109	7.5	53,123	29.8	25,860	15.0
Lung cancer	239,246	0.4	239,246	6.0	16,824	2.1	15,044	2.1	10,908	1.7	239,246	100	5,780	2.6	7,637	3.4	5,491	2.7	10,356	5.8	3,390	2.0
Other lymphomas	225,545	0.4	225,545	5.6	17,453	2.1	9,212	1.3	10,628	1.7	5,780	2.4	225,545	100	3,577	1.6	25,900	12.9	3,866	2.2	2,825	1.6
Colon and rectal cancer	223,757	0.4	223,757	5.6	12,513	1.5	9,782	1.4	10,222	1.6	7,637	3.2	3,577	1.6	223,757	100	2,804	1.4	2,945	1.7	1,906	1.1
Leukemia	200,284	0.4	200,284	5.0	15,038	1.8	7,356	1.0	8,984	1.4	5,491	2.3	25,900	11.5	2,804	1.3	200,284	100	3,167	1.8	2,081	1.2
Head, neck, and throat cancer	178,445	0.3	178,445	4.5	28,055	3.4	4,526	0.6	8,144	1.3	10,356	4.3	3,866	1.7	2,945	1.3	3,167	1.6	178,445	100	2,892	1.7
Thyroid cancer	171,902	0.3	171,902	4.3	6,964	0.9	8,356	1.2	4,029	0.6	3,390	1.4	2,825	1.3	1,906	0.9	2,081	1.0	2,892	1.6	171,902	100
Kidney cancer	159,505	0.3	159,505	4.0	8,603	1.1	5,206	0.7	12,742	2.0	5,589	2.3	2,946	1.3	3,729	1.7	2,537	1.3	1,920	1.1	2,277	1.3
Bladder cancer	148,394	0.3	148,394	3.7	10,429	1.3	4,349	0.6	22,485	3.5	5,361	2.2	3,156	1.4	3,617	1.6	2,825	1.4	1,986	1.1	1,140	0.7
Endouterine cancer	118,827	0.2	118,827	3.0	4,483	0.5	8,766	1.2	852	0.1	2,490	1.0	1,407	0.6	3,136	1.4	1,199	0.6	701	0.4	1,347	0.8
Multiple myeloma and plasmacytoma	113,601	0.2	113,601	2.8	7,299	0.9	4,569	0.6	5,724	0.9	2,279	1.0	7,971	3.5	1,733	0.8	8,574	4.3	1,256	0.7	1,146	0.7
Liver cancer	81,677	0.2	81,677	2.0	4,082	0.5	3,008	0.4	3,267	0.5	3,315	1.4	1,474	0.7	4,677	2.1	1,054	0.5	1,560	0.9	627	0.4
Brain cancer	75,952	0.1	75,952	1.9	2,902	0.4	2,332	0.3	1,374	0.2	2,914	1.2	1,685	0.7	732	0.3	1,128	0.6	983	0.6	669	0.4
Pancreatic cancer	69,364	0.1	69,364	1.7	3,136	0.4	3,159	0.4	3,858	0.6	2,597	1.1	1,337	0.6	2,408	1.1	1,036	0.5	957	0.5	696	0.4
Bone cancer	37,782	0.1	37,782	0.9	4,530	0.6	2,404	0.3	1,961	0.3	2,448	1.0	1,063	0.5	666	0.3	992	0.5	7,630	4.3	592	0.3
Hodgkin lymphoma	34,758	0.1	34,758	0.9	1,632	0.2	1,336	0.2	883	0.1	671	0.3	10,618	4.7	437	0.2	1,534	0.8	485	0.3	501	0.3
<b>THERAPIES DELIVERED IN 2025</b>																						
Hormone therapy	1,266,200	2.4	176,164	4.4	31,563	3.9	27,228	3.8	24,817	3.9	16,234	6.8	11,497	5.1	12,188	5.4	11,548	5.8	7,533	4.2	31,563	3.9
Targeted therapy	772,397	1.4	488,093	12.2	50,459	6.2	200,382	27.7	83,375	13.0	37,737	15.8	30,750	13.6	17,053	7.6	43,390	21.7	14,044	7.9	50,459	6.2
Chemotherapy	458,949	0.9	224,479	5.6	50,535	6.2	30,379	4.2	15,689	2.5	20,581	8.6	20,761	9.2	22,720	10.2	26,457	13.2	13,745	7.7	50,535	6.2
Bisphosphonates	413,344	0.8	121,900	3.0	25,663	3.1	49,231	6.8	9,661	1.5	9,451	4.0	6,110	2.7	4,714	2.1	4,922	2.5	3,241	1.8	25,663	3.1
Radiation therapy	149,311	0.3	139,049	3.5	14,672	1.8	31,255	4.3	32,756	5.1	22,575	9.4	5,790	2.6	7,948	3.6	4,095	2.0	13,894	7.8	14,672	1.8
Immunotherapy	51,972	0.1	29,194	0.7	3,456	0.4	1,193	0.2	2,254	0.4	1,651	0.7	2,493	1.1	553	0.2	3,781	1.9	456	0.3	3,456	0.4
Gene therapy	5,460	0.0	5,246	0.1	675	0.1	105	0.0	304	0.0	95	0.0	1,943	0.9	87	0.0	981	0.5	71	0.0	675	0.1
Other cancer medications	11,289,852	21.0	1,453,987	36.3	250,692	30.7	248,144	34.3	206,542	32.3	125,228	52.3	88,778	39.4	102,151	45.7	85,078	42.5	77,924	43.7	250,692	30.7
<b>PROCEDURES DELIVERED IN 2025</b>																						
Hysterectomy	73,191	0.1	19,335	0.5	1,040	0.1	2,851	0.4	163	0.0	287	0.1	275	0.1	975	0.4	216	0.1	132	0.1	462	0.3
Mastectomy/lumpectomy	68,321	0.1	45,039	1.1	1,804	0.2	43,497	6.0	301	0.0	577	0.2	494	0.2	472	0.2	360	0.2	195	0.1	570	0.3
Lymphadenectomy	50,616	0.1	47,539	1.2	5,348	0.7	2,766	0.4	13,882	2.2	5,633	2.4	812	0.4	1,527	0.7	671	0.3	9,264	5.2	3,849	2.2
Colectomy	45,840	0.1	22,327	0.6	1,348	0.2	1,080	0.1	1,044	0.2	664	0.3	599	0.3	15,474	6.9	453	0.2	319	0.2	217	0.1
Thyroidectomy	24,934	0.0	13,603	0.3	626	0.1	660	0.1	366	0.1	230	0.1	276	0.1	178	0.1	171	0.1	842	0.5	11,674	6.8
Nephrectomy	22,368	0.0	15,464	0.4	528	0.1	360	0.0	1,057	0.2	269	0.1	209	0.1	377	0.2	175	0.1	114	0.1	153	0.1
Prostatectomy	22,244	0.0	20,607	0.5	651	0.1	65	0.0	19,113	3.0	135	0.1	165	0.1	259	0.1	160	0.1	104	0.1	86	0.1
Lobectomy/pneumonectomy	19,693	0.0	14,891	0.4	930	0.1	717	0.1	593	0.1	11,020	4.6	391	0.2	938	0.4	324	0.2	652	0.4	323	0.2
Stem cell transplant	9,337	0.0	7,959	0.2	213	0.0	144	0.0	168	0.0	73	0.0	1,522	0.7	49	0.0	3,459	1.7	56	0.0	56	0.0
Hepatectomy	8,599	0.0	6,623	0.2	240	0.0	184	0.0	207	0.0	161	0.1	79	0.0	1,870	0.8	80	0.0	93	0.1	66	0.0
Resections for other cancers	8,139	0.0	6,043	0.2	1,512	0.2	329	0.0	245	0.0	315	0.1	122	0.1	166	0.1	134	0.1	718	0.4	188	0.1
Pancreatectomy	6,731	0.0	5,400	0.1	193	0.0	170	0.0	241	0.0	117	0.0	90	0.0	198	0.1	60	0.0	53	0.0	42	0.0

<b>SCREENING PROCEDURES 2021-2025</b>																						
Breast cancer screening	5,165,589	9.6	682,112	17.0	156,057	19.1	253,833	35.1	14,862	2.3	37,768	15.8	32,889	14.6	35,354	15.8	24,237	12.1	14,266	8.0	41,018	23.9
Colorectal cancer screening	4,835,222	9.0	800,875	20.0	199,889	24.4	151,388	20.9	130,660	20.4	43,593	18.2	43,475	19.3	87,601	39.2	33,637	16.8	27,361	15.3	32,412	18.9
Cervical cancer screening	2,961,968	5.5	221,665	5.5	46,632	5.7	74,982	10.4	4,813	0.8	8,515	3.6	9,658	4.3	10,252	4.6	7,319	3.7	4,552	2.6	16,739	9.7
Prostate cancer screening	2,535,613	4.7	599,774	15.0	151,185	18.5	12,004	1.7	305,083	47.7	23,673	9.9	29,103	12.9	26,650	11.9	24,314	12.1	23,137	13.0	10,759	6.3
Lung cancer screening	458,212	0.9	80,614	2.0	18,493	2.3	12,807	1.8	14,185	2.2	13,136	5.5	3,072	1.4	3,829	1.7	2,875	1.4	4,896	2.7	2,208	1.3

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 6.** Continued: Co-occurring cancer conditions, cancer-related therapies and medications, and procedures for patients with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2025 – December 31, 2025, and a recorded diagnosis code for a malignant cancer condition between January 1, 2021 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Kidney Cancer <sup>3</sup>		Bladder Cancer <sup>3</sup>		Endouterine Cancer <sup>3</sup>		Multiple Myeloma and Plasmacytoma <sup>3</sup>		Liver Cancer <sup>3</sup>		Brain Cancer <sup>3</sup>		Pancreatic Cancer <sup>3</sup>		Bone Cancer <sup>3</sup>		Hodgkin Lymphoma <sup>3</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	159,505	4.0	148,394	3.7	118,827	3.0	113,601	2.8	81,677	2.0	75,952	1.9	69,364	1.7	37,782	0.9	34,758	0.9
<b>CANCER CONDITIONS (2021-2025)</b>																						
Skin cancer	817,552	1.5	817,552	20.4	8,603	5.4	10,429	7.0	4,483	3.8	7,299	6.4	4,082	5.0	2,902	3.8	3,136	4.5	4,530	12.0	1,632	4.7
Breast cancer	723,400	1.3	723,400	18.1	5,206	3.3	4,349	2.9	8,766	7.4	4,569	4.0	3,008	3.7	2,332	3.1	3,159	4.6	2,404	6.4	1,336	3.8
Prostate cancer	640,257	1.2	640,257	16.0	12,742	8.0	22,485	15.2	852	0.7	5,724	5.0	3,267	4.0	1,374	1.8	3,858	5.6	1,961	5.2	883	2.5
Other cancers	627,355	1.2	627,355	15.7	22,192	13.9	27,971	18.8	25,313	21.3	7,140	6.3	17,262	21.1	12,653	16.7	18,784	27.1	15,470	40.9	2,237	6.4
Metastatic cancer	622,313	1.2	622,313	15.6	32,511	20.4	21,913	14.8	22,560	19.0	14,024	12.3	22,390	27.4	9,954	13.1	28,545	41.2	13,772	36.5	2,218	6.4
Lung cancer	239,246	0.4	239,246	6.0	5,589	3.5	5,361	3.6	2,490	2.1	2,279	2.0	3,315	4.1	2,914	3.8	2,597	3.7	2,448	6.5	671	1.9
Other lymphomas	225,545	0.4	225,545	5.6	2,946	1.8	3,156	2.1	1,407	1.2	7,971	7.0	1,474	1.8	1,685	2.2	1,337	1.9	1,063	2.8	10,618	30.5
Colon and rectal cancer	223,757	0.4	223,757	5.6	3,729	2.3	3,617	2.4	3,136	2.6	1,733	1.5	4,677	5.7	732	1.0	2,408	3.5	666	1.8	437	1.3
Leukemia	200,284	0.4	200,284	5.0	2,537	1.6	2,825	1.9	1,199	1.0	8,574	7.5	1,054	1.3	1,128	1.5	1,036	1.5	992	2.6	1,534	4.4
Head, neck, and throat cancer	178,445	0.3	178,445	4.5	1,920	1.2	1,986	1.3	701	0.6	1,256	1.1	1,560	1.9	983	1.3	957	1.4	7,630	20.2	485	1.4
Thyroid cancer	171,902	0.3	171,902	4.3	2,277	1.4	1,140	0.8	1,347	1.1	1,146	1.0	627	0.8	669	0.9	696	1.0	592	1.6	501	1.4
Kidney cancer	159,505	0.3	159,505	4.0	159,505	100	13,377	9.0	1,598	1.3	1,496	1.3	1,737	2.1	790	1.0	1,611	2.3	990	2.6	313	0.9
Bladder cancer	148,394	0.3	148,394	3.7	13,377	8.4	148,394	100	1,153	1.0	1,496	1.3	1,216	1.5	468	0.6	946	1.4	460	1.2	242	0.7
Endouterine cancer	118,827	0.2	118,827	3.0	1,598	1.0	1,153	0.8	118,827	100	659	0.6	591	0.7	336	0.4	530	0.8	338	0.9	183	0.5
Multiple myeloma and plasmacytoma	113,601	0.2	113,601	2.8	1,496	0.9	1,496	1.0	659	0.6	113,601	100	577	0.7	520	0.7	558	0.8	1,262	3.3	401	1.2
Liver cancer	81,677	0.2	81,677	2.0	1,737	1.1	1,216	0.8	591	0.5	577	0.5	81,677	100	349	0.5	3,813	5.5	492	1.3	190	0.5
Brain cancer	75,952	0.1	75,952	1.9	790	0.5	468	0.3	336	0.3	520	0.5	349	0.4	75,952	100	425	0.6	1,164	3.1	117	0.3
Pancreatic cancer	69,364	0.1	69,364	1.7	1,611	1.0	946	0.6	530	0.4	558	0.5	3,813	4.7	425	0.6	69,364	100	248	0.7	163	0.5
Bone cancer	37,782	0.1	37,782	0.9	990	0.6	460	0.3	338	0.3	1,262	1.1	492	0.6	1,164	1.5	248	0.4	37,782	100	115	0.3
Hodgkins lymphoma	34,758	0.1	34,758	0.9	313	0.2	242	0.2	183	0.2	401	0.4	190	0.2	117	0.2	163	0.2	115	0.3	34,758	100
<b>THERAPIES DELIVERED IN 2025</b>																						
Hormone therapy	1,266,200	2.4	176,164	4.4	8,511	5.3	7,295	4.9	7,347	6.2	7,277	6.4	11,351	13.9	2,574	3.4	5,331	7.7	1,656	4.4	1,942	5.6
Targeted therapy	772,397	1.4	488,093	12.2	17,053	10.7	11,370	7.7	11,710	9.9	30,990	27.3	11,196	13.7	8,343	11.0	5,462	7.9	6,191	16.4	3,648	10.5
Chemotherapy	458,949	0.9	224,479	5.6	5,817	3.6	12,713	8.6	7,411	6.2	9,393	8.3	8,032	9.8	9,505	12.5	11,638	16.8	3,856	10.2	3,317	9.5
Bisphosphonates	413,344	0.8	121,900	3.0	3,393	2.1	3,068	2.1	3,520	3.0	9,141	8.0	2,161	2.6	998	1.3	1,663	2.4	1,608	4.3	526	1.5
Radiation therapy	149,311	0.3	139,049	3.5	4,821	3.0	3,683	2.5	4,884	4.1	3,100	2.7	4,025	4.9	7,227	9.5	3,715	5.4	3,709	9.8	717	2.1
Immunotherapy	51,972	0.1	29,194	0.7	1,543	1.0	6,083	4.1	212	0.2	16,182	14.2	252	0.3	316	0.4	180	0.3	462	1.2	121	0.3
Gene therapy	5,460	0.0	5,246	0.1	101	0.1	424	0.3	16	0.0	2,083	1.8	37	0.0	126	0.2	31	0.0	62	0.2	102	0.3
Other cancer medications	11,289,852	21.0	1,453,987	36.3	71,287	44.7	65,720	44.3	47,183	39.7	55,152	48.5	44,798	54.8	34,366	45.2	40,553	58.5	18,377	48.6	12,759	36.7
<b>PROCEDURES DELIVERED IN 2025</b>																						
Hysterectomy	73,191	0.1	19,335	0.5	301	0.2	481	0.3	9,952	8.4	125	0.1	109	0.1	77	0.1	92	0.1	37	0.1	43	0.1
Mastectomy/lumpectomy	68,321	0.1	45,039	1.1	268	0.2	181	0.1	532	0.4	233	0.2	98	0.1	85	0.1	153	0.2	78	0.2	95	0.3
Lymphadenectomy	50,616	0.1	47,539	1.2	1,821	1.1	3,139	2.1	3,412	2.9	240	0.2	776	1.0	133	0.2	1,673	2.4	1,404	3.7	128	0.4
Colectomy	45,840	0.1	22,327	0.6	581	0.4	535	0.4	783	0.7	265	0.2	391	0.5	93	0.1	321	0.5	93	0.2	68	0.2
Thyroidectomy	24,934	0.0	13,603	0.3	244	0.2	76	0.1	104	0.1	94	0.1	38	0.0	66	0.1	41	0.1	56	0.1	59	0.2
Nephrectomy	22,368	0.0	15,464	0.4	13,771	8.6	1,610	1.1	150	0.1	88	0.1	94	0.1	48	0.1	90	0.1	49	0.1	27	0.1
Prostatectomy	22,244	0.0	20,607	0.5	374	0.2	2,272	1.5	-	<0.1	61	0.1	41	0.1	26	0.0	37	0.1	20	0.1	15	0.0
Lobectomy/Pneumonectomy	19,693	0.0	14,891	0.4	528	0.3	246	0.2	310	0.3	109	0.1	270	0.3	50	0.1	216	0.3	339	0.9	57	0.2
Stem cell transplant	9,337	0.0	7,959	0.2	74	0.0	40	0.0	27	0.0	3,554	3.1	36	0.0	183	0.2	24	0.0	88	0.2	445	1.3
Hepatectomy	8,599	0.0	6,623	0.2	234	0.1	82	0.1	117	0.1	30	0.0	2,276	2.8	28	0.0	1,335	1.9	21	0.1	-	<0.1
Resections for other cancers	8,139	0.0	6,043	0.2	252	0.2	77	0.1	147	0.1	111	0.1	57	0.1	47	0.1	37	0.1	1,288	3.4	17	0.0
Pancreatectomy	6,731	0.0	5,400	0.1	192	0.1	56	0.0	40	0.0	27	0.0	413	0.5	35	0.0	3,978	5.7	17	0.0	-	<0.1

<b>SCREENING PROCEDURES 2021-2025</b>																						
Breast cancer screening	5,165,589	9.6	682,112	17.0	18,910	11.9	12,887	8.7	40,256	33.9	16,099	14.2	8,246	10.1	6,042	8.0	8,756	12.6	3,004	8.0	4,478	12.9
Colorectal cancer screening	4,835,222	9.0	800,875	20.0	31,398	19.7	27,053	18.2	25,202	21.2	20,381	17.9	18,337	22.5	6,885	9.1	12,756	18.4	4,190	11.1	5,746	16.5
Cervical cancer screening	2,961,968	5.5	221,665	5.5	4,887	3.1	3,141	2.1	14,576	12.3	4,137	3.6	2,380	2.9	2,923	3.8	2,257	3.3	1,293	3.4	2,422	7.0
Prostate cancer screening	2,535,613	4.7	599,774	15.0	27,720	17.4	31,607	21.3	1,189	1.0	14,952	13.2	11,172	13.7	3,886	5.1	6,865	9.9	3,345	8.9	3,203	9.2
Lung cancer screening	458,212	0.9	80,614	2.0	3,519	2.2	4,961	3.3	1,243	1.0	1,327	1.2	1,600	2.0	477	0.6	949	1.4	380	1.0	410	1.2

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 7.** Characteristics of patients with malignant cancer conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1 – December 31, 2025, for selected cancer-related therapies and medications provided between January 1, 2025 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Targeted Therapy <sup>3</sup>		Chemotherapy <sup>3</sup>		Hormone Therapy <sup>3</sup>		Radiation Therapy <sup>3</sup>		Bisphosphonates <sup>3</sup>		Immunotherapy <sup>3</sup>		Gene Therapy <sup>3</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	488,093	12.2	224,479	5.6	176,164	4.4	139,049	3.5	121,900	3.0	29,194	0.7	5,246	0.1
<b>CANCER CONDITIONS (2021-2025)</b>																		
Skin cancer	817,552	1.5	817,552	20.4	50,459	10.3	50,535	22.5	31,563	17.9	14,672	10.6	25,663	21.1	3,456	11.8	675	12.9
Breast cancer	723,400	1.3	723,400	18.1	200,382	41.1	30,379	13.5	27,228	15.5	31,255	22.5	49,231	40.4	1,193	4.1	105	2.0
Prostate cancer	640,257	1.2	640,257	16.0	83,375	17.1	15,689	7.0	24,817	14.1	32,756	23.6	9,661	7.9	2,254	7.7	304	5.8
Other cancers	627,355	1.2	627,355	15.7	86,095	17.6	60,990	27.2	33,092	18.8	38,769	27.9	18,784	15.4	5,633	19.3	796	15.2
Metastatic cancer	622,313	1.2	622,313	15.6	176,575	36.2	80,767	36.0	38,269	21.7	64,602	46.5	32,156	26.4	7,798	26.7	1,351	25.8
Lung cancer	239,246	0.4	239,246	6.0	37,737	7.7	20,581	9.2	16,234	9.2	22,575	16.2	9,451	7.8	1,651	5.7	95	1.8
Other lymphomas	225,545	0.4	225,545	5.6	30,750	6.3	20,761	9.2	11,497	6.5	5,790	4.2	6,110	5.0	2,493	8.5	1,943	37.0
Colon and rectal cancer	223,757	0.4	223,757	5.6	17,053	3.5	22,720	10.1	12,188	6.9	7,948	5.7	4,714	3.9	553	1.9	87	1.7
Leukemia	200,284	0.4	200,284	5.0	43,390	8.9	26,457	11.8	11,548	6.6	4,095	2.9	4,922	4.0	3,781	13.0	981	18.7
Head, neck, and throat cancer	178,445	0.3	178,445	4.5	14,044	2.9	13,745	6.1	7,533	4.3	13,894	10.0	3,241	2.7	456	1.6	71	1.4
Thyroid cancer	171,902	0.3	171,902	4.3	8,550	1.8	3,138	1.4	6,350	3.6	2,383	1.7	4,350	3.6	413	1.4	53	1.0
Kidney cancer	159,505	0.3	159,505	4.0	17,053	3.5	5,817	2.6	8,511	4.8	4,821	3.5	3,393	2.8	1,543	5.3	101	1.9
Bladder cancer	148,394	0.3	148,394	3.7	11,370	2.3	12,713	5.7	7,295	4.1	3,683	2.6	3,068	2.5	6,083	20.8	424	8.1
Endometrial cancer	118,827	0.2	118,827	3.0	11,710	2.4	7,411	3.3	7,347	4.2	4,884	3.5	3,520	2.9	212	0.7	16	0.3
Multiple myeloma and plasmacytoma	113,601	0.2	113,601	2.8	30,990	6.3	9,393	4.2	7,277	4.1	3,100	2.2	9,141	7.5	16,182	55.4	2,083	39.7
Liver cancer	81,677	0.2	81,677	2.0	11,196	2.3	8,032	3.6	11,351	6.4	4,025	2.9	2,161	1.8	252	0.9	37	0.7
Brain cancer	75,952	0.1	75,952	1.9	8,343	1.7	9,505	4.2	2,574	1.5	7,227	5.2	998	0.8	316	1.1	126	2.4
Pancreatic cancer	69,364	0.1	69,364	1.7	5,462	1.1	11,638	5.2	5,331	3.0	3,715	2.7	1,663	1.4	180	0.6	31	0.6
Bone cancer	37,782	0.1	37,782	0.9	6,191	1.3	3,856	1.7	1,656	0.9	3,709	2.7	1,608	1.3	462	1.6	62	1.2
Hodgkins lymphoma	34,758	0.1	34,758	0.9	3,648	0.7	3,317	1.5	1,942	1.1	717	0.5	526	0.4	121	0.4	102	1.9
<b>THERAPIES DELIVERED IN 2025</b>																		
Hormone therapy	1,266,200	2.4	176,164	4.4	30,801	6.3	17,737	7.9	176,164	100	9,115	6.6	7,080	5.8	2,542	8.7	418	8.0
Targeted therapy	772,397	1.4	488,093	12.2	488,093	100	78,923	35.2	30,801	17.5	58,818	42.3	46,425	38.1	19,551	67.0	2,387	45.5
Chemotherapy	458,949	0.9	224,479	5.6	78,923	16.2	224,479	100	17,737	10.1	34,883	25.1	12,669	10.4	8,035	27.5	3,357	64.0
Bisphosphonates	413,344	0.8	121,900	3.0	46,425	9.5	12,669	5.6	7,080	4.0	8,484	6.1	121,900	100	5,014	17.2	440	8.4
Radiation therapy	149,311	0.3	139,049	3.5	58,818	12.1	34,883	15.5	9,115	5.2	139,049	100	8,484	7.0	2,627	9.0	730	13.9
Immunotherapy	51,972	0.1	29,194	0.7	19,551	4.0	8,035	3.6	2,542	1.4	2,627	1.9	5,014	4.1	29,194	100	1,818	34.7
Gene therapy	5,460	0.0	5,246	0.1	2,387	0.5	3,357	1.5	418	0.2	730	0.5	440	0.4	1,818	6.2	5,246	100
Other cancer medications	11,289,852	21.0	1,453,987	36.3	285,066	58.4	181,863	81.0	118,552	67.3	103,198	74.2	62,382	51.2	25,002	85.6	4,904	93.5
<b>PROCEDURES DELIVERED IN 2025</b>																		
Hysterectomy	73,191	0.1	19,335	0.5	2,839	0.6	3,296	1.5	1,702	1.0	1,716	1.2	449	0.4	67	0.2	-	<0.1
Mastectomy/lumpectomy	68,321	0.1	45,039	1.1	21,786	4.5	6,948	3.1	1,709	1.0	12,656	9.1	2,629	2.2	69	0.2	-	<0.1
Lymphadenectomy	50,616	0.1	47,539	1.2	6,253	1.3	6,310	2.8	2,779	1.6	5,033	3.6	839	0.7	337	1.2	56	1.1
Colectomy	45,840	0.1	22,327	0.6	2,479	0.5	4,891	2.2	2,272	1.3	1,045	0.8	418	0.3	113	0.4	21	0.4
Thyroidectomy	24,934	0.0	13,603	0.3	820	0.2	401	0.2	646	0.4	543	0.4	228	0.2	27	0.1	-	<0.1
Nephrectomy	22,368	0.0	15,464	0.4	1,659	0.3	1,309	0.6	983	0.6	440	0.3	260	0.2	178	0.6	13	0.2
Prostatectomy	22,244	0.0	20,607	0.5	1,342	0.3	657	0.3	586	0.3	434	0.3	91	0.1	149	0.5	-	<0.1
Lobectomy/pneumonectomy	19,693	0.0	14,891	0.4	2,216	0.5	2,203	1.0	1,175	0.7	766	0.6	433	0.4	72	0.2	18	0.3
Stem cell transplant	9,337	0.0	7,959	0.2	4,201	0.9	6,053	2.7	1,001	0.6	1,431	1.0	680	0.6	1,408	4.8	382	7.3
Hepatectomy	8,599	0.0	6,623	0.2	986	0.2	1,959	0.9	771	0.4	484	0.3	91	0.1	26	0.1	-	<0.1
Resections for other cancers	8,139	0.0	6,043	0.2	1,069	0.2	959	0.4	375	0.2	1,323	1.0	142	0.1	48	0.2	18	0.3
Pancreatectomy	6,731	0.0	5,400	0.1	420	0.1	1,484	0.7	610	0.3	372	0.3	73	0.1	-	<0.1	-	<0.1

<b>SCREENING PROCEDURES 2021-2025</b>																		
Breast cancer screening	5,165,589	9.6	682,112	17.0	105,480	21.6	31,868	14.2	31,687	18.0	18,516	13.3	48,228	39.6	3,486	11.9	270	5.1
Colorectal cancer screening	4,835,222	9.0	800,875	20.0	97,229	19.9	47,890	21.3	44,678	25.4	24,277	17.5	36,048	29.6	5,355	18.3	577	11.0
Cervical cancer screening	2,961,968	5.5	221,665	5.5	33,195	6.8	11,340	5.1	10,544	6.0	6,969	5.0	10,992	9.0	884	3.0	94	1.8
Prostate cancer screening	2,535,613	4.7	599,774	15.0	74,419	15.2	32,010	14.3	27,691	15.7	28,465	20.5	10,903	8.9	5,123	17.5	810	15.4
Lung cancer screening	458,212	0.9	80,614	2.0	8,666	1.8	4,378	2.0	5,245	3.0	3,402	2.4	3,934	3.2	511	1.8	24	0.5

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 8.** Characteristics of patients with malignant cancer conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2025 – December 31, 2025, for selected cancer-related procedures provided between January 1, 2025 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Lymphadenectomy <sup>3</sup>		Mastectomy or Lumpectomy <sup>3</sup>		Colectomy <sup>3</sup>		Prostectomy <sup>3</sup>		Hysterectomy <sup>3</sup>		Nephrectomy <sup>3</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	47,539	1.2	45,039	100	22,327	0.6	20,607	0.5	19,335	0.5	15,464	0.4
<b>CANCER CONDITIONS (2021-2025)</b>																
Skin cancer	817,552	1.5	817,552	20.4	5,348	11.2	1,804	4.0	1,348	6.0	651	3.2	1,040	5.4	528	3.4
Breast cancer	723,400	1.3	723,400	18.1	2,766	5.8	43,497	96.6	1,080	4.8	65	0.3	2,851	14.7	360	2.3
Prostate cancer	640,257	1.2	640,257	16.0	13,882	29.2	301	0.7	1,044	4.7	19,113	92.8	163	0.8	1,057	6.8
Other cancers	627,355	1.2	627,355	15.7	13,620	28.7	2,652	5.9	6,432	28.8	1,105	5.4	7,269	37.6	2,668	17.3
Metastatic cancer	622,313	1.2	622,313	15.6	17,404	36.6	8,900	19.8	8,846	39.6	1,944	9.4	4,885	25.3	2,455	15.9
Lung cancer	239,246	0.4	239,246	6.0	5,633	11.8	577	1.3	664	3.0	135	0.7	287	1.5	269	1.7
Other lymphomas	225,545	0.4	225,545	5.6	812	1.7	494	1.1	599	2.7	165	0.8	275	1.4	209	1.4
Colon and rectal cancer	223,757	0.4	223,757	5.6	1,527	3.2	472	1.0	15,474	69.3	259	1.3	975	5.0	377	2.4
Leukemia	200,284	0.4	200,284	5.0	671	1.4	360	0.8	453	2.0	160	0.8	216	1.1	175	1.1
Head, neck, and throat cancer	178,445	0.3	178,445	4.5	9,264	19.5	195	0.4	319	1.4	104	0.5	132	0.7	114	0.7
Thyroid cancer	171,902	0.3	171,902	4.3	3,849	8.1	570	1.3	217	1.0	86	0.4	462	2.4	153	1.0
Kidney cancer	159,505	0.3	159,505	4.0	1,821	3.8	268	0.6	581	2.6	374	1.8	301	1.6	13,771	89.1
Bladder cancer	148,394	0.3	148,394	3.7	3,139	6.6	181	0.4	535	2.4	2,272	11.0	481	2.5	1,610	10.4
Endometrial cancer	118,827	0.2	118,827	3.0	3,412	7.2	532	1.2	783	3.5	-	<0.1	9,952	51.5	150	1.0
Multiple myeloma and plasmacytoma	113,601	0.2	113,601	2.8	240	0.5	233	0.5	265	1.2	61	0.3	125	0.6	88	0.6
Liver cancer	81,677	0.2	81,677	2.0	776	1.6	98	0.2	391	1.8	41	0.2	109	0.6	94	0.6
Brain cancer	75,952	0.1	75,952	1.9	133	0.3	85	0.2	93	0.4	26	0.1	77	0.4	48	0.3
Pancreatic cancer	69,364	0.1	69,364	1.7	1,673	3.5	153	0.3	321	1.4	37	0.2	92	0.5	90	0.6
Bone cancer	37,782	0.1	37,782	0.9	1,404	3.0	78	0.2	93	0.4	20	0.1	37	0.2	49	0.3
Hodgkin lymphoma	34,758	0.1	34,758	0.9	128	0.3	95	0.2	68	0.3	15	0.1	43	0.2	27	0.2
<b>THERAPIES DELIVERED IN 2025</b>																
Hormone therapy	1,266,200	2.4	176,164	4.4	2,779	5.8	1,709	3.8	2,272	10.2	586	2.8	1,702	8.8	983	6.4
Targeted therapy	772,397	1.4	488,093	12.2	6,253	13.2	21,786	48.4	2,479	11.1	1,342	6.5	2,839	14.7	1,659	10.7
Chemotherapy	458,949	0.9	224,479	5.6	6,310	13.3	6,948	15.4	4,891	21.9	657	3.2	3,296	17.0	1,309	8.5
Bisphosphonates	413,344	0.8	121,900	3.0	839	1.8	2,629	5.8	418	1.9	91	0.4	449	2.3	260	1.7
Radiation therapy	149,311	0.3	139,049	3.5	5,033	10.6	12,656	28.1	1,045	4.7	434	2.1	1,716	8.9	440	2.8
Immunotherapy	51,972	0.1	29,194	0.7	337	0.7	69	0.2	113	0.5	149	0.7	67	0.3	178	1.2
Gene therapy	5,460	0.0	5,246	0.1	56	0.1	-	<0.1	21	0.1	-	<0.1	-	<0.1	13	0.1
Other cancer medications	11,289,852	21.0	1,453,987	36.3	44,624	93.9	41,102	91.3	20,991	94.0	18,967	92.0	17,972	93.0	14,537	94.0
<b>PROCEDURES DELIVERED IN 2025</b>																
Hysterectomy	73,191	0.1	19,335	0.5	4,385	9.2	392	0.9	1,407	6.3	-	<0.1	19,335	100	163	1.1
Mastectomy/lumpectomy	68,321	0.1	45,039	1.1	1,655	3.5	45,039	100	91	0.4	0	0.0	392	2.0	40	0.3
Lymphadenectomy	50,616	0.1	47,539	1.2	47,539	100	1,655	3.7	1,187	5.3	13,754	66.7	4,385	22.7	1,664	10.8
Colectomy	45,840	0.1	22,327	0.6	1,187	2.5	91	0.2	22,327	100	164	0.8	1,407	7.3	446	2.9
Thyroidectomy	24,934	0.0	13,603	0.3	3,190	6.7	91	0.2	38	0.2	25	0.1	45	0.2	29	0.2
Nephrectomy	22,368	0.0	15,464	0.4	1,664	3.5	40	0.1	446	2.0	315	1.5	163	0.8	15,464	100
Prostectomy	22,244	0.0	20,607	0.5	13,754	28.9	0	0.0	164	0.7	20,607	100	-	<0.1	315	2.0
Lobectomy/pneumonectomy	19,693	0.0	14,891	0.4	5,754	12.1	76	0.2	447	2.0	19	0.1	309	1.6	161	1.0
Stem cell transplant	9,337	0.0	7,959	0.2	47	0.1	-	<0.1	41	0.2	-	<0.1	-	<0.1	18	0.1
Hepatectomy	8,599	0.0	6,623	0.2	1,758	3.7	16	0.0	1,127	5.0	-	<0.1	273	1.4	164	1.1
Resections for other cancers	8,139	0.0	6,043	0.2	979	2.1	45	0.1	177	0.8	13	0.1	105	0.5	51	0.3
Pancreatectomy	6,731	0.0	5,400	0.1	1,874	3.9	-	<0.1	309	1.4	-	<0.1	51	0.3	130	0.8

<b>SCREENING PROCEDURES 2021-2025</b>																
Breast cancer screening	5,165,589	9.6	682,112	17.0	3,887	8.2	17,912	39.8	2,786	12.5	-	<0.1	5,649	29.2	1,242	8.0
Colorectal cancer screening	4,835,222	9.0	800,875	20.0	6,534	13.7	8,278	18.4	8,952	40.1	3,255	15.8	3,677	19.0	2,193	14.2
Cervical cancer screening	2,961,968	5.5	221,665	5.5	1,672	3.5	5,273	11.7	898	4.0	-	<0.1	4,088	21.1	367	2.4
Prostate cancer screening	2,535,613	4.7	599,774	15.0	8,554	18.0	113	0.3	1,971	8.8	9,468	45.9	-	<0.1	1,889	12.2
Lung cancer screening	458,212	0.9	80,614	2.0	1,189	2.5	781	1.7	407	1.8	328	1.6	176	0.9	252	1.6

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.

**Table 9.** Continued: Characteristics of patients with malignant cancer conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2025 – December 31, 2025, for selected cancer-related procedures provided between January 1, 2025 – December 31, 2025.<sup>1,2</sup>

	Total Patients		Any Malignant Cancer		Lobectomy or Pneumonectomy <sup>3</sup>		Thyroidectomy <sup>3</sup>		Stem Cell Transplant <sup>3</sup>		Hepatectomy <sup>3</sup>		Resections for Other Cancers <sup>3</sup>		Pancreatectomy <sup>3</sup>	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>UNIQUE PATIENT RECORDS</b>	53,658,310	100	4,001,326	7.5	14,891	0.4	13,603	0.3	7,959	0.2	6,623	0.2	6,043	0.2	5,400	0.1
<b>CANCER CONDITIONS (2021-2025)</b>																
Skin cancer	817,552	1.5	817,552	20.4	930	6.2	626	4.6	213	2.7	240	3.6	1,512	25.0	193	3.6
Breast cancer	723,400	1.3	723,400	18.1	717	4.8	660	4.9	144	1.8	184	2.8	329	5.4	170	3.1
Prostate cancer	640,257	1.2	640,257	16.0	593	4.0	366	2.7	168	2.1	207	3.1	245	4.1	241	4.5
Other cancers	627,355	1.2	627,355	15.7	4,361	29.3	1,296	9.5	975	12.3	2,915	44.0	4,153	68.7	2,518	46.6
Metastatic cancer	622,313	1.2	622,313	15.6	5,062	34.0	3,443	25.3	967	12.1	3,994	60.3	2,192	36.3	2,445	45.3
Lung cancer	239,246	0.4	239,246	6.0	11,020	74.0	230	1.7	73	0.9	161	2.4	315	5.2	117	2.2
Other lymphomas	225,545	0.4	225,545	5.6	391	2.6	276	2.0	1,522	19.1	79	1.2	122	2.0	90	1.7
Colon and rectal cancer	223,757	0.4	223,757	5.6	938	6.3	178	1.3	49	0.6	1,870	28.2	166	2.7	198	3.7
Leukemia	200,284	0.4	200,284	5.0	324	2.2	171	1.3	3,459	43.5	80	1.2	134	2.2	60	1.1
Head, neck, and throat cancer	178,445	0.3	178,445	4.5	652	4.4	842	6.2	56	0.7	93	1.4	718	11.9	53	1.0
Thyroid cancer	171,902	0.3	171,902	4.3	323	2.2	11,674	85.8	56	0.7	66	1.0	188	3.1	42	0.8
Kidney cancer	159,505	0.3	159,505	4.0	528	3.5	244	1.8	74	0.9	234	3.5	252	4.2	192	3.6
Bladder cancer	148,394	0.3	148,394	3.7	246	1.7	76	0.6	40	0.5	82	1.2	77	1.3	56	1.0
Endometrial cancer	118,827	0.2	118,827	3.0	310	2.1	104	0.8	27	0.3	117	1.8	147	2.4	40	0.7
Multiple myeloma and plasmacytoma	113,601	0.2	113,601	2.8	109	0.7	94	0.7	3,554	44.7	30	0.5	111	1.8	27	0.5
Liver cancer	81,677	0.2	81,677	2.0	270	1.8	38	0.3	36	0.5	2,276	34.4	57	0.9	413	7.6
Brain cancer	75,952	0.1	75,952	1.9	50	0.3	66	0.5	183	2.3	28	0.4	47	0.8	35	0.6
Pancreatic cancer	69,364	0.1	69,364	1.7	216	1.5	41	0.3	24	0.3	1,335	20.2	37	0.6	3,978	73.7
Bone cancer	37,782	0.1	37,782	0.9	339	2.3	56	0.4	88	1.1	21	0.3	1,288	21.3	17	0.3
Hodgkins lymphoma	34,758	0.1	34,758	0.9	57	0.4	59	0.4	445	5.6	-	<0.1	17	0.3	-	<0.1
<b>THERAPIES DELIVERED IN 2025</b>																
Hormone therapy	1,266,200	2.4	176,164	4.4	1,175	7.9	646	4.7	1,001	12.6	771	11.6	375	6.2	610	11.3
Targeted therapy	772,397	1.4	488,093	12.2	2,216	14.9	820	6.0	4,201	52.8	986	14.9	1,069	17.7	420	7.8
Chemotherapy	458,949	0.9	224,479	5.6	2,203	14.8	401	2.9	6,053	76.1	1,959	29.6	959	15.9	1,484	27.5
Bisphosphonates	413,344	0.8	121,900	3.0	433	2.9	228	1.7	680	8.5	91	1.4	142	2.3	73	1.4
Radiation therapy	149,311	0.3	139,049	3.5	766	5.1	543	4.0	1,431	18.0	484	7.3	1,323	21.9	372	6.9
Immunotherapy	51,972	0.1	29,194	0.7	72	0.5	27	0.2	1,408	17.7	26	0.4	48	0.8	-	<0.1
Gene therapy	5,460	0.0	5,246	0.1	18	0.1	-	<0.1	382	4.8	-	<0.1	18	0.3	-	<0.1
Other cancer medications	11,289,852	21.0	1,453,987	36.3	13,942	93.6	12,376	91.0	7,833	98.4	6,412	96.8	5,750	95.2	5,253	97.3
<b>PROCEDURES DELIVERED IN 2025</b>																
Hysterectomy	73,191	0.1	19,335	0.5	309	2.1	45	0.3	-	<0.1	273	4.1	105	1.7	51	0.9
Mastectomy/lumpectomy	68,321	0.1	45,039	1.1	76	0.5	91	0.7	-	<0.1	16	0.2	45	0.7	-	<0.1
Lymphadenectomy	50,616	0.1	47,539	1.2	5,754	38.6	3,190	23.5	47	0.6	1,758	26.5	979	16.2	1,874	34.7
Colectomy	45,840	0.1	22,327	0.6	447	3.0	38	0.3	41	0.5	1,127	17.0	177	2.9	309	5.7
Thyroidectomy	24,934	0.0	13,603	0.3	141	0.9	13,603	100	-	<0.1	-	<0.1	116	1.9	-	<0.1
Nephrectomy	22,368	0.0	15,464	0.4	161	1.1	29	0.2	18	0.2	164	2.5	51	0.8	130	2.4
Prostatectomy	22,244	0.0	20,607	0.5	19	0.1	25	0.2	-	<0.1	-	<0.1	13	0.2	-	<0.1
Lobectomy/pneumonectomy	19,693	0.0	14,891	0.4	14,891	100	141	1.0	30	0.4	391	5.9	241	4.0	99	1.8
Stem cell transplant	9,337	0.0	7,959	0.2	30	0.2	-	<0.1	7,959	100	-	<0.1	15	0.2	-	<0.1
Hepatectomy	8,599	0.0	6,623	0.2	391	2.6	-	<0.1	-	<0.1	6,623	100	60	1.0	1,473	27.3
Resections for other cancers	8,139	0.0	6,043	0.2	241	1.6	116	0.9	15	0.2	60	0.9	6,043	100	33	0.6
Pancreatectomy	6,731	0.0	5,400	0.1	99	0.7	-	<0.1	-	<0.1	1,473	22.2	33	0.5	5,400	100

<b>SCREENING PROCEDURES 2021-2025</b>																
Breast cancer screening	5,165,589	9.6	682,112	17.0	2,234	15.0	2,040	15.0	432	5.4	524	7.9	361	6.0	472	8.7
Colorectal cancer screening	4,835,222	9.0	800,875	20.0	2,798	18.8	1,814	13.3	914	11.5	1,346	20.3	570	9.4	811	15.0
Cervical cancer screening	2,961,968	5.5	221,665	5.5	627	4.2	1,003	7.4	214	2.7	165	2.5	144	2.4	132	2.4
Prostate cancer screening	2,535,613	4.7	599,774	15.0	1,221	8.2	675	5.0	1,005	12.6	464	7.0	371	6.1	399	7.4
Lung cancer screening	458,212	0.9	80,614	2.0	1,254	8.4	148	1.1	23	0.3	57	0.9	39	0.6	64	1.2

<sup>1</sup>Total includes 74 partners in PCORnet.

<sup>2</sup>Some totals may not add up due to masking low cell sizes.

<sup>3</sup>Denominator for percentage is the count for all patients with any malignant cancer conditions.